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ABSTRACT 
 
BACKGROUND AND OBJECTIVES 
 
Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of worldwide 
mortality and disability. Physical activity is one of the few modifiable factors that 
decelerate COPD evolution. Nonetheless, the dose and characteristics of physical 
activity responsible for the deceleration are still unknown. In consequence, the 
aims of this thesis are to move forward and refine the methodology and 
instruments to evaluate the physical activity of COPD patients, go in depth in the 
knowledge about the characteristics and the pattern of their physical activity, and 
determine which physical activity characteristics improve the prognosis of COPD 
patients.  
 
 
METHODS 
 
177 patients with stable COPD selected from 8 hospitals in Spain have participated 
(94% male, mean±SD age 71±8 years, forced expiratory volume in 1 s 52±16% 
predicted and body mass index 29±5 kg·m-2). Physical activity was measured with 
an accelerometer (SenseWear® Pro2 Armband) and with a questionnaire (Yale 
Physical Activity Survey, YPAS). The sociodemographic (age, sex, civil status, 
educational level, socioeconomic status, employment status, and tobacco habit) 
and clinical variables (airflow limitation, lung hyperinflation, dyspnoea, gas 
exchange, local and systemic inflammation, body composition, comorbidities, 
quality of life, and exercise capacity), were obtained using validated tools and 
following international standards. Information about the evolution of the disease 
(Hospital Admissions and Mortality) was obtained from government registries.   
 
 
RESULTS 
 
(Objective 1) The YPAS is a valid tool for the detection of COPD patients’ inactivity 
[the area under the ROC curve is 0.71 (95% CI: 0.63–0.79)]. (Objective 2) The 97% 
of COPD patients are able to perform 10-minutes bouts of moderate-to-vigorous 
physical activity. More than 50% of the COPD patients met the World Health 
Organization recommendation of physical activity for the elderly. The quantity of 
physical activity, the percentage of activity done in bouts and the frequency of 
bouts decreased with increasing COPD severity. (Objective 3) The quantity and the 
intensity of physical activity are independent determinants of the COPD evolution. 
Every additional 1000 daily steps at low-average intensity reduce by 20% the risk 
of COPD hospitalisation. However, a greater quantity of daily steps at high-average 
intensity does not influence the risk of COPD hospitalisation (HR 1.01, p=0.919). 
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CONCLUSIONS 
 
The YPAS is a valid instrument for the early screening of COPD patients who run 
the risk of sedentarism. Patients with severe and very severe COPD perform fewer 
bouts of physical activity and less quantity of physical activity, and have lower 
ratio between bouts and quantity than those in mild and moderate stages. Higher 
quantity of low-intensity physical activity reduces the risk of COPD hospitalization.  
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RESUM 
 
ANTECEDENTS I OBJECTIUS 
 
La Malaltia Pulmonar Obstructiva Crònica (MPOC) és una de les principals causes 
de mortalitat i discapacitat a nivell mundial. L'activitat física és un dels pocs factors 
modificables que desacceleren l'evolució de la MPOC. No obstant, la dosi i les 
característiques de l'activitat física responsables de la desacceleració són encara 
desconegudes. En conseqüència, els objectius d'aquesta tesi són avançar i 
perfeccionar la metodologia i els instruments per avaluar l'activitat física 
realitzada pels malalts amb MPOC, aprofundir en el coneixement sobre les 
característiques i els patrons de la seva activitat física i determinar quines 
característiques de l'activitat física milloren el pronòstic dels malalts amb MPOC. 
 
 
MÈTODES 
 
Han participat 177 individus amb MPOC estable seleccionats de 8 hospitals a 
Espanya (94% homes, edat mitjana±DE 71±8 anys, volum expiratori forçat en 1 s 
52±16% i índex de massa corporal 29±5 kg·m-2). L'activitat física va ser mesurada 
per un acceleròmetre (SenseWear® Pro2 Armband) i per un qüestionari (Yale 
Physical Activity Survey, YPAS). Les variables sociodemogràfiques (edat, sexe, 
estat civil, nivell educatiu, nivell socioeconòmic, situació laboral i hàbit tabàquic) i 
les variables clíniques (limitació al flux d'aire, hiperinsuflació pulmonar, díspnea, 
intercanvi de gasos, inflamació sistèmica i local, composició corporal, 
comorbiditats, qualitat de vida i capacitat d'exercici), es van obtenir utilitzant 
instruments validats i seguint les normes internacionals. La informació sobre 
l'evolució de la malaltia (els ingressos hospitalaris i la mortalitat) es va obtenir 
dels registres dels governs. 
 
 
RESULTATS  
 
(Objectiu 1) El YPAS és una eina vàlida per a la detecció precoç de la inactivitat 
dels individus amb MPOC [àrea sota la corba ROC (95% IC) = 0.71 (0,63-0,79)]. 
(Objectiu 2) El 97% dels individus amb MPOC són capaços de realitzar episodis de 
10 minuts d'activitat física moderada-vigorosa. Més del 50% dels individus amb 
MPOC compleixen amb les recomanacions de l'Organització Mundial de la Salut 
sobre l'activitat física per a la gent gran. La quantitat d'activitat física, la proporció 
d'aquesta activitat realitzada en episodis de 10 minuts i la freqüència d'aquests 
episodis va disminuir amb l'augment de la gravetat de la MPOC. (Objectiu 3) La 
quantitat i la intensitat de l'activitat física són determinants independents de 
l'evolució de la MPOC. El risc d'hospitalització per MPOC és un 20% menor per 
cada 1000 passos diaris addicionals realitzats en baixa intensitat. No obstant, una 
major quantitat de passos diaris a una alta intensitat mitjana no influeix en el risc 
d'hospitalització per MPOC (HR = 1.01; p = 0,919). 
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CONCLUSIONS 
 
El YPAS és una eina vàlida per a la detecció precoç dels individus amb MPOC 
físicament inactius. Els pacients amb MPOC greu i molt greu realitzen menys 
episodis i quantitat d'activitat física, i tenen menor la ràtio entre episodis i 
quantitat que en aquells en estat lleu i moderat. Una major quantitat d'activitat 
física de baixa intensitat redueix el risc d'hospitalització per MPOC. 
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RESUMEN 
 
ANTECEDENTES Y OBJETIVOS 
 
La Enfermedad Pulmonar Obstructiva Crónica (EPOC) es una de las principales 
causas de  mortalidad y discapacidad a nivel mundial. La actividad física es uno de 
los pocos factores modificables que desaceleran la evolución de la EPOC. Sin 
embargo, la dosis y las características de la actividad física responsables de la 
desaceleración son todavía desconocidas. En consecuencia, los objetivos de esta 
tesis son avanzar y perfeccionar la metodología e instrumentos para evaluar la 
actividad física realizada por los enfermos con EPOC, profundizar en el 
conocimiento sobre las características y patrones de su actividad física y 
determinar qué características de la actividad física mejoran el pronóstico de los 
enfermos con EPOC. 
 
 
MÉTODOS 
 
Han participado 177 individuos con EPOC estable seleccionados de 8 hospitales en 
España (94% hombre, edad media±DE 71±8 años, volumen espiratorio forzado 
predicho en 1 s 52±16% e índice de masa corporal 29±5 kg·m-2).   La actividad 
física fue medida por un acelerómetro (SenseWear® Pro2 Armband) y por un 
cuestionario (Yale Physical Activity Survey, YPAS). Las variables 
sociodemográficas (edad, sexo, estado civil, nivel educativo, nivel socioeconómico, 
situación laboral y hábito tabáquico) y las variables clínicas (limitación al flujo 
aereo, hiperinsuflación pulmonar, disnea, intercambio de gases, inflamación 
sistémica y local, composición corporal, comorbilidades, calidad de la vida y 
capacidad de ejercicio), se obtuvieron utilizando instrumentos validados y 
siguiendo las normas internacionales. La información sobre la evolución de la 
enfermedad (ingresos hospitalarios y mortalidad) se obtuvo de los registros 
gubernamentales. 
 
 
RESULTADOS 
 
(Objetivo 1) El YPAS es una herramienta válida para la detección precoz de la 
inactividad de los individuos con EPOC [área bajo la curva ROC (95% IC) = 0.71 
(0.63-0.79)]. (Objetivo 2) El 97% de los individuos con EPOC son capaces de 
realizar episodios de 10 minutos de actividad física moderada-vigorosa. Más del 
50% de los individuos con EPOC cumplen con la recomendación de la Organización 
Mundial de la Salud sobre actividad física para las personas mayores. La cantidad 
de actividad física, la proporción de ésta realizada en episodios de 10 minutos y la 
frecuencia de estos episodios disminuyó con el aumento de la gravedad de la EPOC. 
(Objetivo 3) La cantidad y la intensidad de la actividad física son determinantes 
independientes de la evolución de la EPOC. El riesgo de hospitalización por EPOC 
es un 20% menor por cada 1000 pasos adicionales realizados en baja intensidad 
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media. Sin embargo, una mayor cantidad de pasos diarios a una alta intensidad 
media no influye en el riesgo de hospitalización por EPOC (HR = 1.01; p = 0,919). 
 
 
 
 
CONCLUSIONES 
 
El YPAS es una herramienta válida para la detección precoz de los individuos con 
EPOC físicamente inactivos. Los pacientes con EPOC grave y muy grave realizan 
menos episodios y cantidad de actividad física, y tienen menor el ratio entre 
episodios y cantidad que en aquellos en estado leve y moderado. Una mayor 
cantidad de actividad física de baja intensidad reduce el riesgo de hospitalización 
por EPOC. 
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PREFACE  
 
Due to population aging and increased tobacco consumption, a worldwide rise in 
the prevalence of chronic obstructive pulmonary disease (COPD) is expected. 
Physical activity has been found to be one of the few behavioural factors that 
improve COPD evolution. However, the assessment of physical activity and their 
effects upon COPD are still very basic and inaccurate. Therefore, this thesis 
consists in a compilation of three scientific publications attempting to better 
understand how to measure COPD patients' physical activity, what are their 
regular levels of physical activity and which characteristics of physical activity are 
responsible of the deceleration of COPD course. According to the procedures of the 
PhD program of the Department of Salut, Activitat Física i Esport, the thesis 
includes an abstract, a general introduction, a rationale, the objectives, the results 
(3 original scientific papers), a discussion, and final conclusions. The scientific 
papers included in this thesis are based on data from the Phenotype and Course of 
Chronic Obstructive Pulmonary Disease (PAC-COPD) study, a Spanish multi-centric 
cohort study aiming to improve the understanding about the phenotypic 
heterogeneity of COPD and its relationship with the clinical prognosis. At the end 
of this thesis, in annexes, other publications regarding physical activity or 
ambulatory assessment that I have co-authored during the predoctoral period are 
included, altogether with a list of congress contributions. 
 
 
Barcelona, July 2015  
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BACKGROUND 
 
Chronic Obstructive Pulmonary Disease (COPD) 
Definition 
 
Chronic obstructive pulmonary disease (COPD) is a "preventable and treatable 
pulmonary disease with some significant extrapulmonary effects that may 
contribute to the severity in individual patients. Its pulmonary component is 
characterized by airflow limitation that is not fully reversible. The airflow 
limitation is usually progressive and associated with an abnormal inflammatory 
response of the lung to noxious particles or gases" [1].  
 
The airflow limitation that characterizes COPD is usually measured by the ratio 
between forced expiratory volume in one second (FEV1) and forced vital capacity 
(FVC). A ratio below 0.7 (FEV1 / FVC ≤0.70) is the standardized operational 
definition of COPD [2]. Moreover, this reduction of expiratory airflow serves to 
characterize the severity of the disease, being this light, moderate, severe or very 
severe when the FEV1 is ≥80%; 80-50%, 50-30% or <30% of expected according to 
age, sex and height of patients (Table 1) [2]. In addition, following the recognition 
of the multifactoriality of COPD severity, new measures of COPD severity have 
appeared with a more holistic approach. This is the case of the Combined COPD 
Assessment proposed by The Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) that takes into account the airflow limitation, frequency of 
exacerbations, and quality of life (Table 1) [3]. 
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Table 1. Classification of COPD severity according to ATS/ERS guidelines [2] and 
to GOLD initiative [3]. 
 
 ATS/ERS  
classification 
GOLD  
classification 
 
Spirometric 
Classification Risk 
FEV1 ≥ 80 I. Mild COPD A 
(Low Risk & 
Less Symptoms) 
B 
(Low Risk & 
More Symptoms) 
Low Risk 
(FEV1 ≥ 50 & 
≤ 1 Exacerbations) 50≤ FEV1 >80 II. Moderate COPD 
30≤ FEV1 >50 III. Severe COPD C 
(High Risk & 
Less Symptoms) 
D 
(High Risk & 
More Symptoms) 
High Risk 
(FEV1 < 50 or  
≥ 2 Exacerbations) FEV1 < 30 IV. Very severe COPD 
  
Less Symptoms 
(mMRC<2 or 
CAT<10) 
More Symptoms 
(mMRC≥2 or 
CAT≥10) 
 
  
Symptoms 
  
FEV1: predicted post-broncodilatador forced expiratory volume in 1 s; mMRC: modified 
Medical Research Council Disnea scale; CAT:  COPD assessment test 
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Prevalence, morbidity and mortality 
 
In 2006, the worldwide prevalence of COPD in the population older than 40 years 
(~1000 million) was 8-12%, being one of the highest among chronic non-
communicable diseases [4]. Moreover, it is expected that this prevalence increases 
as a result of the changing age structure of populations (the number of people aged 
60 and over will nearly triple in size in 2050) [5], the tobacco abuse during the 
past decades, and the longer life expectancy of patients with COPD achieved 
through the improvement of management of COPD [6]. In 2007, the prevalence of 
COPD in Spain was lower than the worldwide prevalence (7.1% of men and 2% of 
women aged 40-80 years) [7], due to the delayed acquisition of smoking habit, 
especially among women. However, at the same time, in 2007, Spanish people 
were at the head of Europe regarding smoking population, which portends that 
Spain will become in few years one of the developed countries with higher 
prevalence of COPD.  
 
COPD morbidity accounts for 8.2% of medical visits (primary care and external 
consultations), 8.3% of emergency visits and 4.3% of hospitalizations [8], being the 
third and fourth leading cause of hospitalization in men and women older than 45 
years, respectively in Spain [9]. The most frequent cause of COPD morbidity 
(medical consultation and hospital admission) is the COPD exacerbation [2, 10]. 
COPD exacerbation is “an acute event characterized by a worsening of the patient’s 
respiratory symptoms that is beyond normal day-to-day variations and leads to a 
change in medication”[3]. Patients with COPD experience from one to three COPD 
exacerbations on average per year [11–13]. COPD exacerbations increase the 
decline of lung function [14] and jeopardize both quality of life [15] and survival 
amongst these patients [16]. Therefore, reducing the frequency of COPD 
exacerbations is a major therapeutic goal [3]. 
 
COPD mortality is difficult to assess due to the lack of an accepted and 
standardized code for COPD and the limited validity of current death certificates 
[17]. However, COPD is recognized as one of the leading causes of mortality 
worldwide. Between 1990 and 2010, COPD moved from fourth to third leading 
cause of death worldwide, being responsible of more than 8% of deaths due to 
non-communicable diseases [18]. Despite this, life expectancy for smokers in their 
mid-fifties at ten years is 75% amongst smoker adult people with no lung disease, 
65% for people with COPD symptoms, and 63%, 58% and 15% for patients with 
light, moderate, and severe-to-very severe COPD, respectively [19].  
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Prognostic factors of COPD evolution 
 
Several factors play a role in COPD evolution, including biological factors (such as 
airflow limitation, lung hyperinflation, gas exchange, pulmonary hypertension, 
COPD exacerbations, lung infections, deficiency of alpha 1-antitrypsin, and/or 
exercise capacity), pharmacological (such as inhaled steroids, long-acting 
bronchodilators or flu vaccine), environmental (such as air pollution and/or 
occupational exposure) and behavioural (such as tobacco habit, diet and/or 
physical activity) [20–22].  
 
In the current thesis, we focus on physical activity, which depends on individual's 
behaviour and therefore is potentially modifiable, and plays an important role in 
the morbidity and mortality of COPD patients [23]. 
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Physical Activity 
Definition 
 
Physical activity is defined as "any bodily movement produced by skeletal muscles 
that results in energy expenditure" [24]. Physical activity is a complex, modifiable 
and multidimensional behaviour, performed in bouts during occupational and/or 
leisure time, based on personal interests or needs. Physical activity can be 
characterized by the frequency, duration, intensity, amount and type of activity 
performed [55, 56]. It is important to distinguish physical activity from exercise or 
physical fitness. The exercise is the part of physical activity in which planned and 
structured bodily movements are performed to improve or maintain physical 
fitness [24]. Physical fitness is a set of attributes that people have or achieve that 
relates to the ability to perform physical activity [24]. 
 
Physical activity prevents the 9% of premature deaths and the 6-10% of the 
burden of non-communicable diseases [25, 26]. Despite these well-known benefits, 
there is a widespread trend towards rising physical inactivity levels worldwide 
[27]. In 2008, physical inactivity was considered one of the most important public 
health problems, affecting around one-third of adult population worldwide [28] 
and causing approximately 32 million of years lost due to ill-health, disability or 
early death (DALYs) worldwide, representing about 2.1% of global DALYs each 
year [29]. 
 
It could be argued that the elderly population with chronic disease, such as 
patients with COPD, are even more at risk to be affected by the deleterious effects 
of physical inactivity because of their pathophysiological limitations like lung 
hyperinflation, limited gas exchange, recurrent exacerbations, and reduced 
physical fitness [23]. 
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Measurement of physical activity in COPD patients 
 
Accurate assessment of daily physical activity is essential in COPD patients because 
of its effect on disease prognosis [30]. Importantly, the physical activity 
measurement is more complex for COPD patients than for the general population 
because of the abovementioned characteristics, which alter patients’ movement 
efficiency.  
 
The existing tools to measure physical activity include direct (diaries, doubly 
labeled water (DLW), accelerometers) and indirect (oxygen uptake, heart rate, 
body temperature, ventilation monitors, and questionnaires) methods.  Most of 
existing epidemiological studies measured physical activity by questionnaires 
and/or more recently with accelerometers [31].  
 
The questionnaires have allowed the identification of the health benefits of 
physical activity in many chronic diseases and conditions. The questionnaires are 
low cost, easy to use, a unique kind of tool able to assess type and purpose of 
activity, have generalized applicability, and are the elected technique to measure 
physical activity in large epidemiological studies [32–34]. However, they are not 
able to characterise individual-level physical activity because of their poor 
accuracy [31]. 
 
The specific characteristics of COPD patients preclude the use of any physical 
activity questionnaire if it has not been previously validated for this population. 
Before this thesis some questionnaires were used to assess physical activity in 
COPD population [35]. Evidence concerning reliability, validity and responsiveness 
of these questionnaires for COPD physical activity assessment was mainly 
inexistent [30]. Only Vilaró and colleagues [36] validated the Modified Baecke 
Physical Activity Questionnaire specifically for COPD population, but this 
questionnaire is mainly focused on rating the physical activity level (classifying 
subjects in sedentary, moderately sedentary and active) instead of quantifying or 
characterizing the physical activity performed by patients with COPD. 
 
The accelerometer is becoming the most accepted method to measure physical 
activity in COPD patients due to its higher accuracy and reliability at the individual 
level [31]. Accelerometers use the acceleration in the subjects’ movements to 
quantify intensity over short epochs of time. In COPD patients, the accelerometers 
have been shown to have high reliability (Interclass Correlation Coefficient, ICC= 
0.84) between three sequential 6-min walk distances (6MWDs) [37]. 
Accelerometers are able to distinguish between different intensities of physical 
activity and between populations with different amount of physical activity (e.g., 
healthy vs COPD). It has been suggested that accelerometers are more accurate for 
quantification and differentiation of body movements than for estimation of 
energy expenditure, especially at slow speeds [30]. However, using multisensor 
monitors, such as SenseWear® Pro2 Armband, instead of regular accelerometers 
could also provide valid assessments of both physical activity and energy 
expenditure in COPD patients [38]. The responsiveness of accelerometers to 
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interventions has not been evaluated because of the lack of effective interventions 
to increase physical activity in COPD patients.  
 
Other tools are rarely used in COPD patients to study physical activity for several 
reasons. Briefly, diaries are not used because they are burdensome for participants 
and are affected by respondent error and low resolution. Methods based on 
physiological assessments (DLW, oxygen uptake, ventilation rate, heart rate, or 
body temperature) are not appropriate to assess physical activity of COPD patients 
because the physiological response to physical activity depends on movement 
efficiency which change across COPD severity [30]. 
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Characteristics of COPD patients' physical activity 
 
Since the launch of the accelerometers, research on the physical activity of COPD 
patients has consistently shown that COPD patients perform lower volume of 
physical activity than their healthy peers [39, 40]. The changes in physical activity 
start in the early stage of the disease [41, 42], where the speed and intensity of 
walking are the main physical activity aspects affected [43–45]. Only at severe and 
very severe stages of the airflow limitation, the time spent in moderate-to-vigorous 
physical activity is reduced, when compared with healthy subjects [42]. However, 
there are huge differences in physical activity volume across countries [46, 47] 
that cannot be fully explained by severity or age differences.  
 
On the other hand, and despite all previous evidence about the reduction of the 
volume of physical activity in COPD patients, there are no studies providing 
information on what features of the pattern of physical activity explain this 
reduction of physical activity volume. Indeed, this lack of information on the 
pattern of physical activity of COPD patients may have limited our ability to design 
interventions with realistic goals for this population[48].  
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Benefits of physical activity upon COPD 
 
Until 2003 there were almost no evidences regarding the beneficial effects of 
physical activity upon COPD. The lack of a validated tool to measure physical 
activity in this population was one of the reasons. However, from 2003, the 
literature regarding the relationship between physical activity and COPD started 
growing, as well as the consistency of its beneficial effect, despite of the limited 
accuracy of the used questionnaires [23]. It is worth noting the beneficial effects 
found in longitudinal designs about COPD morbidity [44, 49–55] and mortality [52, 
53, 56–60], where those COPD patients that spent 2 hours or more per week 
performing physical activity had a 30% and 20% reduction in risk of 
hospitalization and death because of COPD, respectively, compared to those who 
did not achieve these 2 hours per week [52].  Furthermore, it is also remarkable 
the cross-sectional associations found between physical activity and forced 
expiratory volume [61, 62], dyspnoea [62, 63], health-related quality of life [56, 62, 
64, 65], exercise capacity [47, 63, 66, 67] or systemic inflammation [41, 63, 68]. 
However, and despite the evidences on the relationship between keeping 
physically active and COPD evolution, it remains unexplained what is the required 
dose of physical activity, whether there is a minimum necessary threshold of 
physical activity, whether the benefit is independent of the type of physical 
activity, or whether this benefit depends on the stage of disease severity.  
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RATIONALE 
 
 
COPD has become a challenge for the health systems that it is expected to worsen 
in the future due to population aging and the widespread abuse of tobacco 
consumption. Without dismissing the importance of anti-tobacco health policies, 
we need parallel measures that help to prevent COPD development or decelerate 
COPD course. Physical activity is one of the most promising factors because of its 
susceptibility of modification through behavioural interventions and because its 
demonstrated effects on COPD evolution.  
 
However, there are important gaps in the knowledge about physical activity and 
COPD which prevent the design and implementation of interventions to achieve 
the precise dose of physical activity that could improve COPD evolution [48]. 
Specifically, there is a lack of a free, quick, accurate and specifically validated tool 
to quantify physical activity in COPD patients. Also, the characteristics of physical 
activity pattern in COPD patients have never been assessed. Finally, it what is not 
known, is the potential differential role of the several characteristics of physical 
activity on its beneficial effect on COPD course.  
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OBJECTIVES 
 
 
General Objective 
 
The present thesis aims to deep and improve the knowledge about the measure 
and effects of physical activity in COPD patients, specifically to move forward and 
refine the methodology and instruments to evaluate the physical activity of COPD 
patients, go in depth in the knowledge about the characteristics and pattern of 
their physical activity, and determine which characteristics of their physical 
activity are responsible of decelerating the COPD evolution. 
 
To reach our objective, two physical activity measures were included, one self-
reported measured using the Yale Physical Activity questionnaire and another 
objectively measured with the SenseWear® Pro2 Armband accelerometer, in a 
cohort of COPD patients thoroughly characterized who participated in the 
Phenotype and Course of Chronic Obstructive Pulmonary Disease (PAC-COPD) 
study. 
 
Specific Objectives 
 
 
1. To study the validity of the Yale Physical Activity questionnaire to quantify and 
classify physical activity levels in COPD patients.  
 
2. To describe the overall physical activity volume and pattern of physical activity 
bouts in patients with COPD. 
 
3. To assess how the overall physical activity volume and pattern of physical 
activity bouts differ according to airflow limitation of COPD patients. 
 
4. To explore whether COPD patients meet the general guidelines for physical 
activity for elderly.  
 
5. To assess the independent effect of the quantity and intensity of physical 
activity on the risk of hospitalisation due to a COPD exacerbation. 
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HYPOTHESES 
 
 
The Yale Physical Activity questionnaire is a valid instrument to quantify the 
volume of physical activity at the population level and determine inactive COPD 
patients.  
 
The volume and characteristics of COPD patients' physical activity pattern differ 
across the severity of airflow limitation. COPD patients with severe and very 
severe airflow limitation perform their daily activities in fewer and shorter bouts 
than those with mild and moderate stages. 
 
COPD patients that usually perform higher quantity and intensity of physical 
activity have lower risk of hospitalization for COPD exacerbation than those 
performing lower quantity or intensity of physical activity. 
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RESULTS 
 
 
Paper I: Validation of the Yale Physical Activity Survey in Chronic Obstructive 
Pulmonary Disease patients 
 
 
Donaire-Gonzalez D, Gimeno-Santos E, Serra I, Roca J, Balcells E, Rodríguez E, 
Farrero E, Antó JM, Garcia-Aymerich J; on behalf of PAC-COPD Study Group. 
Validation of the Yale Physical Activity Survey in chronic obstructive pulmonary 
disease patients. Arch Bronconeumol. 2011;47(11):552-60.* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* This paper is reproduced according to the original print version.  
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Paper II: Physical activity in COPD patients: patterns and bouts 
 
Donaire-Gonzalez D, Gimeno-Santos E, Balcells E, Rodríguez DA, Farrero E, de 
Batlle J, Benet M, Ferrer A, Barberà JA, Gea J, Rodriguez-Roisin R, Antó JM, Garcia-
Aymerich J. Physical activity in COPD patients: patterns and bouts. Eur Respir J. 
2013;42(4):993-1002. * 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* This paper is reproduced according to the original print version.  
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SAMPLE SIZE CALCULATIONS 
 
Sample size calculations were performed with the program GRANMO 7.10 [1] and 
using data from previous research on physical activity from the SenseWear® Pro2 
Armband accelerometer in COPD patients [2,3]. 
 
For the estimation of physical activity levels, 163 subjects would have to be recruited 
to obtain values of steps per day with a precision of +/- 500 units (steps) for an 
estimated standard deviation of 3000 in the population, assuming that such 
population is equal to 999999 subjects, accepting an alpha risk of 0.05 for a two-sided 
test, and anticipating a non-responses rate of 15%. Similarly, and using the same 
assumptions, 99 subjects would be needed to estimate values of minutes per day in 
activity with a precision of +/- 15 units (minutes) for an estimated standard deviation 
of 70 in the population. 
 
Regarding the study of differences across severity groups, the above maximum 
estimated figure of 163 would allow identifying as statistically significant differences 
greater than or equal to 1500 steps between two groups of severity, which is lower 
than differences reported in the literature, accepting an alpha risk of 0.05 and a beta 
risk of 0.2 in a two-sided test. 
 
Finally, the estimated figure of 163 would allow identifying a proportion of 50% or 
lower in the adherence to physical activity recommendations with a precision of +/- 7 
units, under the same assumptions stated above. 
 
The total available sample of 177 COPD patients exceeded the requirements and 
therefore allows answering the research questions.  
   
58 
 
 
R FUNCTION TO CALCULATE BOUTS OF PHYSICAL ACTIVITY 
 
Description 
The function pabout identifies the bouts performed for an individual, gives the total days 
registered (n), and characterizes their bouts with the median intensity (METs), duration 
(min/bout), and time (day).  
 
Usage  
pabout(int,tim,database) 
 
Arguments 
 
int a numeric value specifying the intensity threshold (in METs) of the bouts 
tim a numeric value specifying the minimal duration (in minutes) of the bouts 
database name of the accelerometer data.frame in R 
 
 
The accelerometer data.frame is unique for each subject and includes a row per minute, 
being all minutes consecutive, with information on only two variables: date (as POSIXt 
class) and mets, as follows: 
 
date mets 
2006-09-13 13:32:00 1.216434121 
2006-09-13 13:33:00 1.407135248 
2006-09-13 13:34:00 1.327723145 
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2006-09-13 13:35:00 1.191337228 
2006-09-13 13:36:00 0.908973336 
2006-09-13 13:37:00 1.057457089 
2006-09-13 13:38:00 0.896382630 
2006-09-13 13:39:00 0.890199065 
…  
 
Results 
The function results in a database with a single row per each physical activity bout with the 
following variables: 
 
id.bout identification number of bout 
intensity median energy expenditure (METs) per physical activity bout 
duration mean time spent per physical activity bout (minutes/bout) 
day day when physical activity bouts where registered 
ndays total number of days registered 
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Function 
 
pabout <-function(int,tim,database) 
{ 
 require(doBy) 
 names(database)<-tolower(names(database)) 
 
 if (!is.numeric(int)|!is.numeric(tim)) 
  stop("\n variable 'int'&'tim' must be a numeric") 
 
 if (!is.data.frame (database)) 
  stop("\n variable 'database' must be a data.frame") 
 
 if (sum(names(database)=="mets")==0) 
  stop("\n No variable called 'mets' in 'database'") 
 
 if (sum(names(database)=="date")==0) 
  stop("\n No variable called 'date' in 'database'") 
 
 if (!any(class(database$date)=="POSIXt")) 
  stop("\n variable 'date' in 'database' must be a POSIXt") 
  
 if(!max(difftime(tail(database$date,n=-1),head(database$date,n=-
1),units="mins"))==1) 
  stop("\n variable 'date' in 'database' must be contain consecutive 
minutes") 
  
with(database,{ 
pa <- 0 
pa[mets>=int] <- 1 
 
duration<-rep.int(rle(pa)$lengths, rle(pa)$lengths) 
day<- format(date,format="%Y-%m-%d") 
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nbout<-NA 
 
bout<-data.frame(id.bout=0,intensity=NA,duration=NA, 
day=0,ndays=length(rle(as.character(day))$values)) 
 
if(length(rle(pa)$lengths[rle(pa)$values==1 & 
rle(pa)$lengths>=tim])!=0){ 
nbout[duration >=tim & pa ==1]<- 
rep.int(1:length(rle(pa)$values[rle(pa)$values==1 & 
rle(pa)$lengths>=tim]), 
rle(pa)$lengths[rle(pa)$values==1 & 
rle(pa)$lengths>=tim]) 
 
bout<-data.frame(id.bout=1:max(nbout,na.rm=T), 
intensity=sapply(1:max(nbout,na.rm=T),function(y) 
median(mets[nbout==y],na.rm=T)), 
duration=rle(pa)$lengths[rle(pa)$values==1 & 
rle(pa)$lengths>=tim], 
day=sapply(as.data.frame(unclass(table(day,nbout))),whi
ch.max), 
ndays=length(rle(as.character(day 
[!is.na(day)]))$values) 
) 
bout} 
}) 
} 
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ADDITIONAL RESULTS (PAPER II) 
 
Table S1. Characteristics of physical activity bouts in COPD patients using standard 
definition of intensity.  
 
 
Moderate-to-vigorous 
intensities 
  (≥ 3 METs)* 
  median (25th-75th percentile) 
Characteristics of physical activity bouts    
Participation in physical activity bouts, n 
(%) 168 (95%) 
Frequency (bouts·day-1) † 2.2 (1-3.9) 
Duration (min·bout-1) † 21 (16-27) 
Intensity (METs) † 3.8 (3.5-4.0) 
Time in bouts (min·day-1) † 45 (17-91) 
Time in bouts out of total time in activity 
(%)† 29 (16-49) 
 
n: number; m: mean; SD: standard deviation; MET: metabolic equivalent tasks. 
* Standard definition of intensity of physical activity [4]. 
 
† The frequency, duration, intensity, time in bouts, and time in bouts out of total time in activity were 
only computed for subjects that had at least one bout in the whole recording period 
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Figure S1. Frequency, duration, and time in physical activity bouts of moderate-to-
vigorous intensities using standard definition of intensity, across levels of COPD 
severity 
 
* p-trend across COPD severity stages <0.05. 
† p-value comparing mild-to-moderate versus severe-to-very severe COPD <0.05. 
‡ Only patients who participated in bouts. 
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Figure S2. COPD patients adherence to physical activity recommendations for older 
adults* using standard definition of physical activity intensity†. 
 
 
 
 
* Moderate-intensity physical activity for a minimum of 30 min on five days each week or vigorous-
intensity aerobic activity for a minimum of 20 min on three days each week [5]. 
†  3 METs for moderate and 6 METs for vigorous physical activity [4]. 
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Table S2. Self-reported (Yale Physical Activity Survey) time spent weekly in physical activities, according to the adherence to physical 
activity recommendations for older adults* defined using standard cut-offs of intensity†. 
 
 Adherence to physical activity standard recommendations  
 
No 
Yes, 
accumulated in 
bouts ≥10 min 
Yes, 
in consecutive min 
p-value 
n= 85 (50%) n= 40 (24%) n= 44 (26%)  
Household activities (h·week-1), m (SD) 8.2 (8.1) 11.7 (13.6) 10.6 (11) 0.322 
Work activities (h·week-1), m (SD) 4.5 (12.7) 3.6 (14.1) 5.8 (14.4) 0.53 
Leisure time activities (h·week-1), m (SD) 12.3 (11.4) 15.4 (10.6) 18 (13.9) 0.007 
     Yard work/gardening (h·week-1), m (SD) 1.5 (4.7) 1.7 (4.3) 4.6 (13.7) 0.255 
     Caretaking (h·week-1), m (SD) 1.1 (4.6) 0.3 (1.4) 0.8 (3.3) 0.519 
     Exercise (h·week-1), m (SD) 1.2 (4) 1.8 (3.8) 1 (2.3) 0.281 
     Recreational activities (h·week-1), m (SD) 8.5 (9.3) 11.5 (9.3) 11.5 (6.4) 0.001 
* Moderate-intensity physical activity for a minimum of 30 min on five days each week or vigorous-intensity aerobic activity for a minimum of 20 min on three days 
each week [5] 
† Standard cut-offs of intensity of physical activity: 3 METs for moderate and 6 METs for vigorous physical activity [4]. 
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ONLINE SUPPLEMENT (PAPER III) 
 
BENEFITS OF PHYSICAL ACTIVITY ON CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE HOSPITALISATION DEPEND ON INTENSITY 
David Donaire-Gonzalez, Elena Gimeno-Santos, Eva Balcells, Jordi de Batlle, Maria 
A Ramon, Esther Rodriguez, Eva Farrero, Marta Benet, Stefano Guerra, Jaume 
Sauleda, Antoni Ferrer, Jaume J Ferrer, Joan A Barberà, Robert Rodriguez-Roisin, 
Joaquim Gea, Alvar Agustí, Josep M Antó, Judith Garcia-Aymerich, and the PAC-
COPD Study Group. 
 
METHODS (complete version) 
RESULTS: 
• Table E1. Characteristics of physical activity at baseline, according to outcomes 
(hospitalisation or death) during follow-up. 
• Table E2. Characteristics of physical activity of the patients at baseline, 
according to levels of COPD severity. 
•  Table E3. Characteristics of physical activity at baseline, according to intensity 
and COPD hospitalisation during follow-up. 
• Table E4. Adjusted association between physical activity quantity (steps per day) 
and COPD hospitalisation, according to spirometric COPD severity (multivariate 
Cox proportional hazards regression). 
• Table E5. Adjusted association between physical activity quantity (steps per 
day) and COPD hospitalisation, according to having had a COPD hospitalisation 
in the previous 12 months (multivariate Cox proportional hazards regression). 
• Table E6. Adjusted association between volume and intensity of physical 
activity and COPD hospitalisation (multivariate Cox proportional hazards 
regression). 
• Table E7. Adjusted association between physical activity quantity (steps per 
day) and COPD hospitalisation, after excluding patients with extreme values 
(>95th percentile) in steps per day (multivariate Cox proportional hazards 
regression). 
• Table E8. Adjusted association between physical activity quantity (steps per day) 
and COPD hospitalisation or all-cause mortality (multivariate Cox proportional 
hazards regression). 
• Table E9. Adjusted association between physical activity variables and all-cause 
hospitalisation (multivariate Cox proportional hazards regression). 
• Table E10. Adjusted association between physical activity quantity (steps per day) 
and COPD hospitalisation categorising intensity in three groups (multivariate Cox 
proportional hazards regression). 
SUPPLEMENT REFERENCES 
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METHODS (complete version) 
 
Study Design, Participants and Ethics 
The design, methodology and main results of the “Phenotype characterisation and 
course of chronic obstructive pulmonary disease” (PAC-COPD) study have been 
reported before[1, 2]. In brief, COPD patients were enrolled during their first 
hospitalisation due to COPD exacerbation in nine teaching hospitals in Spain. 
Patients were evaluated three months after discharge, when clinically stable 
(baseline). The diagnosis of COPD was established according to the ATS-ERS 
guidelines (post-bronchodilator forced expiratory volume in the first second to 
forced vital capacity ratio (FEV1/FVC) <0.70). Patients were invited to participate 
in a second visit for follow-up assessment 18-24 months later while clinically 
stable. From 251 patients who were participating in the PAC-COPD study in this 
second visit, 177 (70%) accepted to measure PA with an activity monitor (see 
below). There were no differences between them and those who did not 
participate, as previously shown[3]. All patients were followed up until December 
31st, 2010 or date of death, whichever came first (median 2.6 years). The Ethics 
Committees of all the participating hospitals approved the study, and written 
informed consent was obtained from all subjects. 
 
Measurements 
Patients were instructed to wear an accelerometer (SenseWear® Pro2 Armband. 
SWA; Body Media, Pittsburgh, PA) placed on the right arm during waking hours 
(aprox, from 8.00 am through 10.00 pm) in 8 consecutive days, just after the 
clinical examination (described below). On average, they wore the accelerometer 
six days, and recorded a mean of 95% of daytime (13.5 h of 14 h maximum)[4]. 
This device provides minute by minute information on subjects’ movements and 
physiological response, which allowed obtaining measures of quantity and 
intensity of PA. The quantity of PA was assessed using: (i) the number of steps per 
day, (ii) the number of days per week that the patient could be considered 
physically active, operationally defined by ≥ 5000 steps per day[5, 6]; and (iii) time 
(minutes) per day spent in PA (defined as any minute with ≥ 1.5 Metabolic 
Equivalent Tasks (METs)). The intensity of PA was assessed by the average of 
METs during the time spent in PA. 
 
We obtained information about hospitalisations (dates and diagnoses on 
discharge) during the 12 months prior to enrollment (i.e. from 2005 to 2006) and 
during follow up (from 2006 until December 31st, 2010), from the Minimum Basic 
Dataset (CMBD) that covers all Spanish hospitals. We defined a COPD 
hospitalisation as any hospitalisation whose primary cause of hospitalisation at 
discharge corresponds to codes 490-496, or primary cause is 466 or 518.81 if 
second cause was 491.21, according to the International Classification of Diseases, 9th 
revision. 
 
As reported elsewhere in detail[1] other measurements included socio-
demographic factors, pharmacologic and non-pharmacologic treatment (e.g., 
pulmonary rehabilitation, long-term oxygen therapy), smoking habit, dietary 
habits, co-morbidities (Charlson index), health-related quality of life (St George 
Respiratory Questionnaire (SGRQ)), dyspnoea (modified Medical Research Council 
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dyspnoea scale (mMRC)), complete lung function (including forced spirometry 
(post-bronchodilator FEV1, FVC, FEV1/FVC), static lung volumes by body 
plethysmography (residual volume (RV), total lung capacity (TLC), RV/TLC), 
single-breath carbon monoxide lung diffusing capacity (DLco), and arterial blood 
gases), nutritional status (body mass index (BMI) and fat free mass index (FFMI) 
by body impedance), exercise tolerance (six-min walking distance (6MWD) and 
oxygen consumption (VO2max) during a cardiopulmonary incremental exercise 
test with cycloergometer), lung density, emphysema quantification and 
semiquantitative evaluation of bronchial wall thickness from computarised 
tomographies, and systemic inflammation (C-reactive protein (CRP) and tumor 
necrosis factor alpha (TNF-α)). 
 
Statistical analysis 
Provided sample size was fixed by the primary scientific objectives of the PAC-
COPD Study, prior to any analysis we calculated the statistical power to answer our 
research question with 177 patients using the software GRANMO 7.10. Accepting 
an alpha risk of 0.05 in a two-sided test, and using own data about the distribution 
of physically active:physically inactive COPD patients[3], the statistical power was 
84% to recognise as statistically significant a risk reduction in COPD 
hospitalisation similar to that reported in previous literature[7]. 
 
Results are presented as mean (standard deviation), n (%) or median (25th-75th 
percentile), as appropriate. The relationship between baseline PA variables and 
risk of COPD hospitalisation was first tested using the Kruskal Wallis test and then 
using Cox proportional hazards regression models. To test the independent effect 
of quantity and intensity of PA, we stratified the association between the three 
quantity variables and COPD hospitalisation according to intensity levels 
(categorised by its median value in our population (≥2.7 METs)). Because the 
effect of quantity variables was restricted to the low average intensity group, 
multivariate models included an interaction term between each variable of PA 
quantity and intensity. Potential confounders considered in the analysis were sex, 
age, education, marital status, family members, working status, socio-economic 
status, inhaled treatment (bronchodilators and corticosteroids), smoking status, 
smoking duration and intensity, Charlson index, cardiovascular comorbidities 
(ischaemic heart disease, cardiac heart failure or cerebrovascular disease), 
dyspnoea score, health-related quality of life, COPD hospitalisations in the 
previous 12months, FEV1, FVC, RV/TLC, DLco, PaO2, BMI, FFMI, 6MWD, VO2max, 
lung density and structure, CRP, TNF-α, participation in a pulmonary rehabilitation 
programme, and consumption of fruits, vegetables and cured meats. Final 
multivariate models were built, adjusting for variables that were independently 
associated with the outcome (p<0.05) or modified the coefficient estimate for the 
exposure (>10% change). The proportionality of Cox models was checked by 
plotting the Schoenfeld residuals of each predictor variable of the model according 
to survival time. Collinearity between variables was checked by the variance 
inflation factor approach. 
 
To test for potential effect modification, final models were stratified according to 
(i) severity of airflow limitation (above and below 50% FEV1)[8], and (ii) having 
had a COPD hospitalisation in the previous year. We performed additional analysis 
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using the volume of physical activity (METs-min per day) as the exposure. As 
sensitivity analyses, we repeated all analyses (i) excluding subjects with extreme 
values (>95th percentile) in the accelerometer measures, (ii) using COPD 
hospitalisation or all-cause mortality as the outcome, (iii) using all-cause 
hospitalisation as the outcome, and (iv) categorising PA intensity in three groups. 
All analyses were conducted using R 3.0.1 (R Foundation for Statistical Computing, 
Vienna, Austria). 
   
 
Table E1. Characteristics of physical activity at baseline, according to outcomes (hospitalisation or death) during follow-up. 
 
 
No COPD 
hospitalisation 
COPD 
hospitalisation 
Death before 
hospitalisation 
n= 100 n= 67 n= 10 
m (SD) m (SD) m (SD) 
Steps per day 7705 (4597) 5339 (3890) 5115 (7496) 
Physically active days/week, median (25th-75th 
percentile) 
6 (2 - 7) 2 (0 - 7) 1 (0 - 4) 
Time in PA (min/day) 190 (129) 160 (108) 135 (149) 
Average intensity of PA (METs) 2.8 (0.5) 2.8 (0.6) 2.8 (0.6) 
n: number; m: mean; SD: standard deviation; MET: metabolic equivalent tasks. 
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Table E2. Characteristics of physical activity of the patients at baseline, according to levels of COPD severity. 
 
 
Mild COPD Moderate COPD Severe COPD 
Very Severe 
COPD   
 n=9 (5%) n=87 (49%) n=64 (36%) n=17 (10%) 
 m (SD) m (SD) m (SD) m (SD) p-value p- trend 
Steps per day 9755 (4968) 7233 (4721) 5793 (3786) 5381 (6318) 0.010 0.032 
Physically active days/week*, median (25th-75th 
percentile) 
6 (6 - 7) 6 (1 - 7) 4 (0 - 7) 1 (0 - 6) 0.017 0.010 
Time in PA (min/day) 220 (117) 186 (117) 157 (105) 169 (198) 0.061 0.337 
Average intensity of PA (METs) 3.1 (0.6) 2.8 (0.5) 2.8 (0.5) 2.5 (0.5) 0.069 0.058 
n: number; m: mean; SD: standard deviation; p-value: significance of Kruskal Wallis test comparing the four groups; p-trend: significance of the linear trend 
across COPD severity stages, treating the COPD severity stages as a interval variable; MET: metabolic equivalent tasks.  
* Physically active days defined as ≥5000 steps per day[5] (see methods). 
84
 
 
   
 
Table E3. Characteristics of physical activity at baseline, according to intensity and COPD hospitalisation during follow-up. 
 
 
Low Intensity (average <2.7 METs) 
  
  
  
High Intensity (average ≥2.7 METs) 
All  
No COPD 
hospitalisatio
n 
COPD 
hospitalisatio
n 
p-
value 
All  
No COPD 
hospitalisatio
n 
COPD 
hospitalisatio
n 
p-
value 
n= 86 n= 54 n= 32 n= 86 n= 53 n= 33 
m (SD) m (SD) m (SD) m (SD) m (SD) m (SD) 
Steps per day 4797 (3397) 5751 (3670) 3253 (2182) 0.001  8550 (5038) 9188 (5455) 7487 (4114) 0.250 
Physically active days/week,  
median (25th-75th percentile) 
2 (0 - 6) 5 (1 - 7) 0 (0 - 2) <0.001  7 (4 - 7) 7 (4 - 7) 7 (2 - 7) 0.795 
Time in PA (min/day) 140 (112) 154 (124) 116 (86) 0.116  212 (123) 216 (131) 205 (111) 0.901 
Average intensity of PA (METs) 2.4 (0.2) 2.4 (0.2) 2.3 (0.2) 0.002  3.2 (0.4) 3.2 (0.4) 3.2 (0.4) 0.894 
n: number; m: mean; SD: standard deviation; MET: metabolic equivalent tasks. 
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Table E4. Adjusted association between physical activity quantity (steps per day) and COPD hospitalisation, according to 
spirometric COPD severity (multivariate Cox proportional hazards regression). 
 
  
Mild-to-moderate 
(FEV1≥50%) 
Severe-to-very severe (FEV1<50%) 
n=96; n events= 20 n= 81; n events= 47 
HR (95% CI) p-value HR (95% CI) p-value  
Steps per day (change for each 1000 steps per day) 0.87 (0.77-1.00) 0.042 0.66 (0.51-0.84) 0.001 
High average intensity of PA (≥2.7 METs) 2.46 (0.95-6.39) 0.064 3.08 (1.13-8.36) 0.028 
Interaction: Steps x Intensity - - 1.61 (1.22-2.13) 0.001 
At least one COPD hospitalisation in the previous 12 
months 
2.81 (0.76-10.39) 0.122 8.01 (3.98-16.15) <0.001 
R2=0.08 R2=0.39 
n: number; n events: number of COPD patients who have had a COPD hospitalisation during follow-up; HR: hazard ratio; MET: metabolic equivalent tasks. 
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Table E5. Adjusted association between physical activity quantity (steps per day) and COPD hospitalisation, according to having had 
a COPD hospitalisation in the previous 12 months (multivariate Cox proportional hazards regression). 
 
  
Previous COPD hospitalisation No previous COPD hospitalisation 
n= 29; n events= 23 n= 148; n events= 44 
HR (95% CI) p-value HR (95% CI) p-value 
Steps per day (change for each 1000 steps per 
day) 
0.80 (0.56-1.13) 0.205 0.79 (0.66-0.95) 0.012 
High average intensity of PA (≥2.7 METs) 3.00 (1.13-7.94) 0.027 2.03 (0.79-5.23) 0.140 
Interaction: Steps x Intensity 1.43 (0.96-2.13) 0.077 1.26 (1.03-1.54) 0.023 
FEV1 (% predicted) 0.96 (0.92-1.00) 0.034 0.97 (0.95-0.99) 0.004 
 R2=0.42 R2=0.15 
n: number; n events: number of COPD patients who have had a COPD hospitalisation during follow-up; HR: hazard ratio; MET: metabolic equivalent tasks; FEV1: 
forced expiratory volume in the first second. 
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Table E6. Adjusted association between volume and intensity of physical activity 
and COPD hospitalisation (multivariate Cox proportional hazards regression). 
 
  All subjects 
n= 177; n events= 67 
HR (95% CI) 
p-
value 
Volume of physical activity (METs-min per 
day) 
0.91 (0.84-0.98)    0.009 
High average intensity of PA (≥2.7 METs) 2.54 (1.20-5.36)    0.015 
Interaction: Energy Expenditure x Intensity 1.10 (1.02-1.19)    0.011 
At least one COPD hospitalisation in the 
previous 12 months 
5.10 (2.91-8.91) <0.001 
FEV1 (% predicted) 0.96 (0.94-0.98) <0.001 
R2=0.32 
n: number; n events: number of COPD patients who have had a COPD hospitalisation during follow-
up; HR: hazard ratio; MET: metabolic equivalent tasks; FEV1: forced expiratory volume in the first 
second. 
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Table E7. Adjusted association between physical activity quantity (steps per day) 
and COPD hospitalisation, after excluding patients with extreme values (>95th 
percentile) in steps per day (multivariate Cox proportional hazards regression). 
 
n= 166; n events=  66 
HR (95% CI) p-value 
Steps per day (change for each 1000 steps per day) 0.79 (0.66-0.93) 0.006 
High average intensity of PA (≥2.7 METs) 2.27 (1.15-4.48) 0.018 
Interaction: Steps x Intensity 1.34 (1.10-1.64) 0.003 
At least one COPD hospitalisation in the previous 12 
months 
5.31 (3.02-9.32) <0.001 
FEV1 (% predicted) 0.96 (0.94-0.98) <0.001 
R2=0.33 
n: number; n events: number of COPD patients who have had a COPD hospitalisation during follow-
up; HR: hazard ratio; MET: metabolic equivalent tasks; FEV1: forced expiratory volume in the first 
second. 
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Table E8. Adjusted association between physical activity quantity (steps per day) 
and COPD hospitalisation or all-cause mortality (multivariate Cox proportional 
hazards regression). 
 
All subjects 
n= 177; n events= 77 
HR (95% CI) p-value 
Steps per day (change for each 1000 steps per day) 0.76 (0.65-0.89) 0.001 
High average intensity of PA (≥2.7 METs) 3.02 (1.44-6.33) 0.004 
Interaction: Steps x Intensity 1.31 (1.10-1.56) 0.002 
At least one COPD hospitalisation in the previous 12 
months 
4.70 (2.76-8.01) <0.001 
FEV1 (% predicted) 0.97 (0.95-0.98) <0.001 
R2=0.34 
n: number; n events: number of COPD patients who have had a COPD hospitalisation or died (all-
cause) during follow-up; HR: hazard ratio; MET: metabolic equivalent tasks; FEV1: forced 
expiratory volume in the first second. 
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Table E9. Adjusted association between physical activity quantity (steps per day) 
and all-cause hospitalisation (multivariate Cox proportional hazards regression). 
 
 
All subjects 
n= 177; n events= 102 
HR (95% CI) p-value 
Steps per day (change for each 1000 steps per day) 0.86 (0.77-0.96) 0.006 
High average intensity of PA (≥2.7 METs) 1.90 (1.13-3.21) 0.016 
Interaction: Steps x Intensity 1.16 (1.03-1.31) 0.018 
At least one COPD hospitalisation in the previous 12 
months 
3.32 (2.06-5.37) <0.001 
FEV1 (% predicted) 0.98 (0.97-0.99) 0.005 
R2=0.23 
n: number; n events: number of COPD patients who have had a hospitalisation (all-cause) during 
follow-up; HR: hazard ratio; MET: metabolic equivalent tasks; FEV1: forced expiratory volume in the 
first second. 
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Table E10. Adjusted association between physical activity quantity (steps per day) 
and COPD hospitalisation categorising intensity in tertiles (multivariate Cox 
proportional hazards regression). 
 
All subjects 
n= 177; nº events= 77 
HR (95% CI) p-value 
Steps per day (change for each 1000 steps per day) 0.83 (0.64-1.07) 0.153 
Average intensity of PA:   
Average intensity of PA 1.81 – 2.39 METs 1.59 (0.44-5.73) 0.482 
Average intensity of PA 2.40– 2.69 METs ref  
Average intensity of PA ≥2.7 METs 3.15 (1.27-7.82) 0.013 
Interaction: Steps x Intensity:   
Interaction: Steps x Intensity 1.81 – 2.39 METs  0.99 (0.70-1.39) 0.933 
Interaction: Steps x Intensity 2.40– 2.69 METs ref  
Interaction: Steps x Intensity ≥2.7 METs 1.21 (0.93-1.58) 0.159 
At least one COPD hospitalisation in the previous 12 
months 
5.16 (2.96-9.00) <0.001 
FEV1 (% predicted) 0.96 (0.94-0.98) <0.001 
R2=0.33 
n: number; n events: number of COPD patients who have had a COPD hospitalisation during follow-
up; HR: hazard ratio; MET: metabolic equivalent tasks; FEV1: forced expiratory volume in the first 
second. 
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SUMMARY AND GENERAL DISCUSSION 
 
This section is meant to be a global discussion, avoiding reiterating what has been 
already discussed in each of the papers conforming this doctoral thesis. Therefore, 
this section will build up and expand upon previous discussions on: (i) which has 
been the contribution of this thesis about the role of physical activity in COPD; (ii) 
which have been the main troubles and limitations that we have faced; (iii) which 
are the clinical implications of this thesis; and finally, (iv) which are the research 
implications of this thesis in order to improve the knowledge on the role of 
physical activity in COPD course.  
 
Contribution to the current knowledge  
 
Physical Activity Measurement of COPD patients 
 
Contribution of Paper I & II 
 
Before this thesis started, only the Baecke Physical Activity Questionnaire had 
been validated for the Spanish COPD population [36]. Although the Baecke 
Questionnaire is the most utilized questionnaire to study COPD patients physical 
activity [39], it is mainly focused on rating the physical activity level (classifying 
subjects in sedentary, moderately sedentary and active) instead of quantifying or 
characterizing it. Therefore, amongst all the current methods to assess physical 
activity in people with COPD, this thesis has added a valid questionnaire for both 
the surveillance of the physical activity volume of COPD populations and the 
screening of physical inactive COPD patients.  
 
On the other hand, regarding the objective assessment of physical activity in COPD 
patients, there were only experimental studies showing high validity of 
accelerometers to assess physical activity performed by COPD patients when this 
thesis began. Therefore, there was no guidance on the minimum requirements to 
obtain a valid and reliable accelerometer assessment of regular physical activity 
performed by COPD patients. As a consequence, one of our contributions, and in 
agreement with other studies published during this thesis [42, 69], has been the 
reporting that any combination of three days of physical activity provides a high 
reliable estimate of COPD patients’ physical activity.  
 
Before this thesis started, the adaptation of objective physical activity assessment 
to COPD patients’ capacities (walking speed) was only applied by Coronado and 
colleagues [70]. In this sense, we have taken one step forward through the 
adaptation of physical activity definition according to the aerobic capacity, 
following the American College Sport Medicine criterion [71]. Furthermore, and 
taking advantage of this objective assessment, we have introduced the evaluation 
of the pattern of physical activity bouts in COPD population, which, as explained 
later, has become a crucial improvement to understand how physical activity 
differs according to the degree of the air obstruction severity of COPD patients.  
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Last but not least important, the second paper of this thesis was the first study that 
combined a subjective and an objective physical activity assessment to achieve a 
comprehensive assessment of the quantification of physical activity [71, 72]. 
 
Volume and Pattern of Physical Activity in COPD patients 
 
Contribution of Paper II 
 
When the present thesis started, Pitta and colleagues had shown that COPD 
patients walk less and slowly than healthy patients [73]. In 2009, two cross-
sectional studies described the physical activity volume across severity of airflow 
obstruction [42, 74] showing that there is a significant difference in the volume of 
physical activity across severity of the airflow limitation. Furthermore, they found 
that the reduction in the moderate-to-vigorous physical activity volume of COPD 
patients in relationship to healthy patients began to be statistically significant from 
the GOLD stage II of airflow obstruction. 
 
Our research shows that COPD patients of all spirometric severity stages engage in 
moderate-to-vigorous physical activity bouts during their daily life activities and 
more than a half of them reach the World Health Organization recommendation of 
physical activity to promote or maintain physical health. Thanks to this thesis, we 
also know that the reduction in the volume of physical activity across severity of 
airflow obstruction is because of the reduction in the frequency rather than the 
duration of moderate-to-vigorous physical activity bouts, which is not made up for 
the rest of the overall physical activity. Moreover, we have shown that those COPD 
patients with more severe airflow obstruction experienced a reduction in the 
percentage of the volume of physical activity performed in bouts out of overall 
physical activity. Finally, we have shown that the leisure physical activity is the 
first and the most affected domain/purpose of physical activity amongst COPD 
patients. 
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Benefits of Physical Activity upon COPD Patients evolution 
 
Contribution of Paper III 
 
As mentioned in the introduction section, since 2003 and despite using inaccurate 
assessment tools, low levels of physical activity have been consistently associated 
with higher risk of COPD exacerbations and mortality [23]. In consequence, and 
because of the low precision of questionnaires [34], the appropriate dose required 
to maximize physical activity benefits upon COPD evolution is still a matter of 
study. 
 
The third paper of this thesis was the first study that unraveled the independent 
role of the quantity and the intensity of physical activity upon the risk of COPD 
hospitalizations, using an objective physical activity measurement. The results 
support linear dose-response relationship between quantity of low-intensity 
physical activity and the risk of COPD hospitalisations. However, the finding that 
high quantity of high-intensity physical activity may be unhelpful for COPD 
patients with severe-to-very severe airflow limitation was unexpected and will 
require replication. In the light of these results, future studies should take into 
account the quantity and intensity of physical activity separately since otherwise it 
could reduce the observed magnitude of the association between physical activity 
and COPD hospitalization risk.  
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Strengths and Limitations 
 
The use of the PAC-COPD cohort allowed the follow-up of a large and 
representative sample of incipient COPD patients. They had been systematically 
recruited during their first hospitalization due to a COPD exacerbation. This 
recruitment approach prevented a possible selection bias that might have 
happened if other recruitment strategies had been used (e.g., selecting patients at 
outpatient clinics, rehabilitation settings or lung function laboratories). Moreover, 
the extensive clinical, radiological and biological characterization of participants 
within the frame of the PAC-COPD study [75] allowed the control for confounders, 
which usually are very difficult to obtain in clinical epidemiology research. 
 
The choice of a historic questionnaire, which asks specifically for each activity of 
daily life, instead of a recall questionnaire, which asks about self-perceived 
intensities, was a clear improvement in both internal and external validity of 
physical activity measurement because the intensities of activities remain almost 
constant, while self-perception of intensity depends mainly on physical fitness of 
COPD patients. The SenseWear® Pro2 Armband was the most precise objective 
tool to assess the physical activity performed by COPD subjects. It is a multi-sensor 
worn on the arm allowing to capture light activities of daily life such as personal 
care and it has been shown to be valid specifically for COPD patients [38] and in 
comparison to indirect calorimeter [76]. The evaluation of aerobic capacity prior 
to definition of physical activity thresholds of the objective assessment together 
with the intensive monitoring of at least 12 hours per day during a period of eight 
consecutive days are a guarantee of the validity of the physical activity 
measurement. The combination of the subjective and objective physical activity 
assessments, together with the development of a new computational method to 
assess physical activity bouts have been clear improvements in the validity of the 
study of physical activity patterns in comparison with previous studies. These 
measurements allow both the characterization of the frequency, duration, 
intensity, type and purpose of physical activity and the study of the relationship 
between the overall and bouts of physical activity.  
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A potential limitation of this study is that physically inactive COPD patients could 
have been overrepresented because physical inactivity is a risk factor of COPD 
hospitalization and patients were recruited during a COPD hospitalization. It could 
be argued that, as a consequence of the PAC-COPD design, the volume and range of 
physical activity could have been underestimated, and the relationship between 
physical activity and subsequent COPD hospitalisations underestimated or 
overestimated depending to the dose-response relationship between them (Figure 
1). A second limitation related to subjects' selection is that physical activity 
assessment was done 24 months after the start of PAC-COPD study, i.e., 24 months 
after the first COPD hospitalization, which increased the chance of survival bias. 
Actually, 12 patients died during their first hospitalization and 19 died after 
engaging in the PAC-COPD study but before the physical activity assessment. The 
likelihood that lost patients were less physically active could have reduced more 
the range of physical activity and changed again the estimated relationship 
between physical activity and COPD hospitalization (Figure 1). 
 
Figure 1. The sampling and survival effect on the dose-response analysis between 
physical activity and COPD hospitalization. 
 
Explanation: data from the literature support that the effect of physical activity upon 
COPD hospitalization can follow a radical (solid line) or sigmoidal (dashed line) 
dose-response shape [77, 78]. The shaded area at the right of the figure represents 
that patients with high levels of physical activity were not included in our study 
because recruitment was done during a COPD admission (see text). The shaded area 
at the left of the figure represents that patients with very low levels of physical 
activity were not included in our study because they died during follow-up (see 
text). The two dotted lines represent the association between physical activity and 
COPD hospitalization as estimated in our study. Differences between each dotted 
line and its corresponding radical or sigmoidal lines support overall validity of our 
estimates, although magnitude of the effect of physical activity may be slightly 
different for some specific physical activity levels.  
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A second set of limitations is related to the methods used to assess physical 
activity. The technological restriction of the objective tool to assess certain 
activities like cycling or swimming was a limitation of the present objective 
physical activity evaluation. This weakness would affect more those COPD patients 
who are more active and led to undervaluing the benefits of physical activity upon 
COPD evolution. It is known that SenseWear® Pro2 Armband overestimates the 
intensity of arm activities, which could lead to some differential misclassification if 
the prevalence of these activities were related to some characteristics of COPD. 
However, it must be noted that the Paper I of this thesis shows no differences 
between the questionnaire and the physical activity monitor according to COPD 
characteristics. Furthermore, a single week of physical activity monitoring may 
have resulted in some non-differential misclassification because of seasonal 
variation and/or low representativeness of that particular week.  
 
The lack of repeated measures of physical activity may have prevented to establish 
the causal relationship between physical activity and COPD hospitalization. Putting 
together previous hospitalizations and current physical activity levels will not 
remove all residual confounding, because the relationship between these two 
determinants could be also confounded by previous physical activity levels, as it 
was previously suggested by Garcia-Aymerich and colleagues [58].   
 
Finally, the male predominance in our cohort (94%), which is in agreement with 
COPD gender distribution in Spain, prevented the generalization of the found 
benefits of physical activity upon COPD hospitalisation to the females, because 
there is evidence of sex-related differences in the effects of physical activity [79]. 
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Implications for Clinical Practice 
 
This thesis has direct, relevant, inexpensive and feasible implications for clinical 
practice. Once demonstrated the beneficial effects of physical activity on the 
evolution of COPD (Paper III), the relevance to implement interventions that 
promote physical activity from the early stages of the disease is evident. Thanks to 
the YPAS validation (Paper I), the health care systems have a valid, effective, free 
and easy tool for the early identification of COPD patients physically inactive. 
Moreover, and thanks to the findings of Paper II, it is known that the first domain 
of physical activity that will manifest a reduction and needs promotion is the 
leisure time. Consequently, a systematic anamnesis of leisure time physical activity 
might also help to identify the COPD patients at risk of physical inactivity. 
 
Having been highlighted the need for physical activity promotion and being the 
ability to identify its target population, the next aim is to define the type of 
intervention. According to the findings of Paper II, interventions must be directed 
to increase the total amount of physical activity undertaken by COPD patients by 
performing new bouts of physical activity during leisure time, instead of extending 
the already performed bouts. The activities promoted should be especially focused 
on resistance capacity, being the long duration and light-to-moderate intensity 
activities the most desirable according to the findings of Paper III. Furthermore, as 
a consequence of the different physical activity levels observed across countries 
and populations, interventions designed for COPD patients should not only be 
based on pathophysiology-related limitations but also on the ‘‘subjects’ needs, 
goals, and initial abilities’’, as advocated by the recommendations [8, 9]. Therefore, 
it will be advisable the prescription of achievable amounts of physical activity, as it 
occurs with a pharmacologic treatment, for the prevention of accelerated COPD 
course. Finally, to assess the effectiveness of physical activity interventions several 
physical activity outcomes should be considered, including the proportion of 
patients meeting certain physical activity goals [80], the extra steps per day [81], 
and the changes, if any, in average intensity. 
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Implications for future research 
 
To date, epidemiological and clinical studies have consistently shown that higher 
volume of physical activity reduces the risk of mortality and hospitalization in 
COPD patients [23]. However, the potential role of physical activity in other 
relevant health outcomes of COPD patients is still unknown. In addition, the causal 
nature of some of the reported relationship needs to be established. The next 
paragraphs will provide some insight on the contributions of this thesis to future 
research that will need to fill in the gaps on physical activity and COPD. These 
contributions are mostly in the area of study design and assessment of physical 
activity. 
 
Study Design 
 
During this thesis we have identified several limitations common to most existing 
studies about effects of physical activity on COPD evolution that could be overcome 
by using alternative study designs and/or subjects' selection. These limitations 
cover: (i) residual confounding, including that related to physical activity levels 
prior to study design; (ii) potential for reverse causation as an explanation of study 
findings; and (iii) outcome misclassification because of the lack of information 
about exacerbations characteristics (e.g., viral or bacterial infection, other). 
 
One of the potential solutions solving two of the mentioned limitations is to 
complement existing information coming from prospective cohort studies with 
randomized controlled trials to assess the role of physical activity on COPD 
evolution. The use of stratified or covariate adaptive randomization would help to 
prevent differences between groups regarding infrequent factors, such as not 
having suffered previous COPD hospitalization or the severity of these previous 
COPD hospitalizations [82]. The most important challenge for this proposal is the 
identification of an appropriate intervention to modify physical activity, which in 
turn would lead to reduce exacerbations. Several recent and ongoing initiatives 
can help in this regard [81, 83]. 
 
An additional possibility to reduce confounding by early events in COPD course 
and reducing the potential reverse causation interpretation is to select COPD 
patients at early stages of the disease, ideally before its clinical manifestation. A 
cohort study of long-term heavy smokers in their mid-fifties, without a history 
of COPD exacerbations, would allow not only to improve the study of temporal 
relationship between physical activity and COPD hospitalizations, but also the 
assessment of determinants of physical activity changes over time. However, such 
a study requires a large sample and a long follow-up [84, 85]. 
 
 
Finally, given the anti-inflammatory properties of physical activity [63], it is likely 
that its effects are restricted to exacerbations with high inflammatory burden, such 
as viral or bacterial infections. Therefore, a thorough characterization of COPD 
exacerbations, irrespective of study design and subjects’ selection, is a must for 
all future research studies.  
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Physical Activity assessment 
 
The current thesis builds the assessment of physical activity (and its effects) on the 
Caspersen’s definition of physical activity, which, as detailed in the Introduction, 
clearly delimitates between physical activity, exercise and physical fitness. 
However, results from this thesis as well as ongoing research in other areas reveal 
that a more holistic approach for physical activity is needed if we want to succeed 
in understanding the concept, measuring it and assessing its effects. Among other 
theories, the crisis theory and its Individual Zone of Optimal Functioning model 
deserve discussion for their potential applicability to COPD. They define physical 
activity as a multidimensional behaviour broken down in physiological 
(behavioural & biological components) and psychological (cognitive & affective 
components) dimensions [86]. The behavioural component is characterized by the 
volume, frequency, duration, intensity, and type of physical activity performed. The 
biological component contextualizes the behavioural one regarding the physical 
fitness of patients (aerobic capacity, strength, flexibility, and resistance). The 
cognitive component assesses subjects’ beliefs upon each physical activity 
(frustration, fear, tolerance, and/or voluntary participation). Finally, the affective 
component characterizes the social part of each physical activity (support, 
interaction, and/or recognition).  
 
To date, research in COPD has mostly focused on the physiological dimension of 
physical activity, though still with a restricted approach. To improve its 
assessment, future studies should consider a more detailed measurement of its 
behavioural component, including the type of activity in addition to frequency, 
duration and intensity, using accelerometers on different parts of the body and/or 
applying machine learning algorithms [87]. The identification of the type of activity 
would help to study whether different types of activities have different impact on 
disease evolution [88, 89], and will allow the improvement of the estimation of the 
activity intensity [90]. In the specific case of questionnaires aimed to quantify 
physical activity, there is still no clear answer regarding how to adapt the task-
related intensities distinctive of able-bodied population to disabled population, 
such as COPD patients [91–94]. 
 
Regarding the biological component of the physiological dimension, future studies 
need to incorporate fitness capacity evaluation in order to standardize the physical 
activity intensity with respect to each individual capabilities [71, 95]. This would 
make future studies about the effects of physical activity intensity more 
comparable and replicable between them, and at the same time, it would also allow 
to study the potentially different effect of aerobic and anaerobic physical activity 
upon COPD hospitalization. Interestingly, the fitness assessment and distinction 
between aerobic and anaerobic activities could be incorporated into physical 
activity questionnaires.  
 
The potential role of the psychological dimension of physical activity on COPD 
evolution is underexplored, although it can be hypothesized that part of the 
benefits of physical activity come from the cognitive and affective components [89, 
96]. To delve into this dimension of physical activity, some studies based on 
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healthy subjects and young people have begun to simultaneously evaluate the 
location and physical activity in order to contextualize the activity [97]. At the 
same time, other studies have gone a step further and have included emotional 
momentary assessment tools to capture the emotional and affective components of 
the activities undertaken by individuals [98]. Finally, the addition of information 
regarding desirability to physical activity questionnaires would help controlling 
the over- and underreporting of physical activity.  
 
Overall, the integration of the several dimensions of physical activity and their 
components, both using questionnaires and activity monitors, will help to 
understand this behaviour as a whole and will increase our ability to assess its 
health effects. 
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CONCLUSIONS 
 
1. The Yale Physical Activity Survey is a valid tool for classifying the physical 
activity in patients with COPD, but not for quantifying it.  
 
2. The summary index of the Yale Physical Activity Survey should be considered a 
screening instrument for identifying patients who run the risk of sedentarism. 
 
3. COPD patients of all spirometric severity stages engage in physical activity 
bouts of moderate-to-vigorous intensities.  
 
4. Patients with severe and very severe COPD perform fewer bouts and less 
quantity of physical activity, and have lower ratio between bouts and quantity 
than those in mild and moderate stages.  
 
5. Higher quantity of low-intensity physical activity reduces the risk of COPD 
hospitalization.  
 
6. High-intensity daily-life physical activity does not generate additional 
protective effects in the most severe COPD patients. 
 
   
105 
 
   
106 
 
REFERENCES 
 
1.  Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, 
Jenkins C, Rodriguez-Roisin R, Van Weel C, Zielinski J. Global Strategy for the 
Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary 
Disease GOLD Executive Summary. Am. J. Respir. Crit. Care Med. 2007; 176: 
532–555. 
 
2.  Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and 
treatment of patients with COPD: a summary of the ATS/ERS position paper. 
Eur. Respir. J. 2004; 23: 932–946. 
 
3.  Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, 
Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin 
R. Global strategy for the diagnosis, management, and prevention of chronic 
obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. 
Care Med. 2013; 187: 347–365. 
 
4.  Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, 
Menezes AMB, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik 
A, Nizankowska-Mogilnicka E, BOLD Collaborative Research Group. 
International variation in the prevalence of COPD (the BOLD Study): a 
population-based prevalence study. Lancet 2007; 370: 741–750. 
 
5.  Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, 
Connell C, Jemal A, Lee TA, Miravitlles M, Aldington S, Beasley R. 
Epidemiology and costs of chronic obstructive pulmonary disease. Eur. Respir. J. 
2006; 27: 188–207. 
 
6.  Mannino DM, Kiri VA. Changing the burden of COPD mortality. Int. J. Chron. 
Obstruct. Pulmon. Dis. 2006; 1: 219–233. 
 
7.  Miravitlles M, Soriano JB, García-Río F, Muñoz L, Duran-Tauleria E, Sanchez G, 
Sobradillo V, Ancochea J. Prevalence of COPD in Spain: impact of undiagnosed 
COPD on quality of life and daily life activities. Thorax 2009; 64: 863–868. 
 
8.  Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive 
pulmonary disease surveillance--United States, 1971-2000. Respir. Care 2002; 
47: 1184–1199. 
 
9.  Encuesta de morbilidad hospitalaria. Altas, estancia media, edad media al alta y 
tasa por 100.000 habitantes, según sexo y la causa 2011 [Internet]. Instituto 
Nacional de Estadística; 2011Available from: 
http://www.ine.es/inebmenu/mnu_salud.htm. 
 
10.  Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, 
Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, 
Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, 
   
107 
 
Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero 
LH, Bartels DH, Basáñez M-G, Baxter A, Bell ML, Benjamin EJ, et al. 
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 
1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. 
Lancet 2012; 380: 2197–2223. 
 
11.  Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle 
weakness is related to utilization of health care resources in COPD patients. Eur 
Respir J 1997; 10: 417–423. 
 
12.  Poole PJ, Bagg B, Brodie SM, Black PN. Characteristics of patients admitted to 
hospital with chronic obstructive pulmonary disease. N Z Med J 1997; 110: 272–
275. 
 
13.  Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson 
NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. 
Ann Intern Med 1987; 106: 196–204. 
 
14.  Makris D, Moschandreas J, Damianaki A, Ntaoukakis E, Siafakas NM, Milic 
Emili J, Tzanakis N. Exacerbations and lung function decline in COPD: new 
insights in current and ex-smokers. Respir Med 2007; 101: 1305–1312. 
 
15.  Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, Verea H, 
Murio C, Ros F, Vidal R, IMPAC Study Group. Effect of exacerbations on quality 
of life in patients with chronic obstructive pulmonary disease: a 2 year follow up 
study. Thorax 2004; 59: 387–395. 
 
16.  Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive 
pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67: 957–
963. 
 
17.  Mannino DM, Brown C, Giovino GA. Obstructive lung disease deaths in the 
United States from 1979 through 1993. An analysis using multiple-cause 
mortality data. Am J Respir Crit Care Med 1997; 156: 814–818. 
 
18.  Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, 
Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, 
Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, 
Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth 
F, Bolliger I, Boufous S, Bucello C, Burch M, et al. Global and regional mortality 
from 235 causes of death for 20 age groups in 1990 and 2010: a systematic 
analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–
2128. 
 
19.  Shavelle RM, Paculdo DR, Kush SJ, Mannino DM, Strauss DJ. Life expectancy 
and years of life lost in chronic obstructive pulmonary disease: Findings from the 
NHANES III Follow-up Study. Int J Chron Obstruct Pulmon Dis 2009; 4: 137–
148. 
 
   
108 
 
20.  Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and 
prevention. Lancet 2007; 370: 786–796. 
 
21.  Godtfredsen NS, Vestbo J, Osler M, Prescott E. Risk of hospital admission for 
COPD following smoking cessation and reduction: a Danish population study. 
Thorax 2002; 57: 967–972. 
 
22.  de Batlle J, Mendez M, Romieu I, Balcells E, Benet M, Donaire-Gonzalez D, 
Ferrer JJ, Orozco-Levi M, Antó JM, Garcia-Aymerich J, PAC-COPD Study 
Group. Cured meat consumption increases risk of readmission in COPD patients. 
Eur Respir J 2012; 40: 555–560. 
 
23.  Gimeno-Santos E, Frei A, Steurer-Stey C, de Batlle J, Rabinovich RA, Raste Y, 
Hopkinson NS, Polkey MI, van Remoortel H, Troosters T, Kulich K, Karlsson N, 
Puhan MA, Garcia-Aymerich J, on behalf of PROactive consortium. 
Determinants and outcomes of physical activity in patients with COPD: a 
systematic review. Thorax 2014; 69: 731–739. 
 
24.  Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and 
physical fitness: definitions and distinctions for health-related research. Public 
Health Rep Wash DC 1974 1985; 100: 126–131. 
 
25.  Lee I-M, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT. Effect of 
physical inactivity on major non-communicable diseases worldwide: an analysis 
of burden of disease and life expectancy. Lancet 2012; 380: 219–229. 
 
26.  WHO. Glogal Health Risks: Mortality and Burden of Disease Attributable to 
Selected Major Risks [Internet]. [cited 2012 May 11].Available from: 
http://www.who.int/healthinfo/global_burden_disease/global_health_risks/en/inde
x.html. 
 
27.  Kohl HW 3rd, Craig CL, Lambert EV, Inoue S, Alkandari JR, Leetongin G, 
Kahlmeier S. The pandemic of physical inactivity: global action for public health. 
Lancet 2012; 380: 294–305. 
 
28.  Hallal PC, Andersen LB, Bull FC, Guthold R, Haskell W, Ekelund U. Global 
physical activity levels: surveillance progress, pitfalls, and prospects. Lancet 
2012; 380: 247–257. 
 
29.  WHO | Prevalence of insufficient physical activity [Internet]. WHO [cited 2013 
May 17]. Available from: 
http://www.who.int/gho/ncd/risk_factors/physical_activity_text/en/index.html. 
 
30.  Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. 
Quantifying physical activity in daily life with questionnaires and motion sensors 
in COPD. Eur. Respir. J. 2006; 27: 1040–1055. 
 
31.  Prince SA, Adamo KB, Hamel ME, Hardt J, Gorber SC, Tremblay M. A 
comparison of direct versus self-report measures for assessing physical activity in 
adults: a systematic review. Int. J. Behav. Nutr. Phys. Act. 2008; 5: 56. 
   
109 
 
 
32.  Lamonte MJ, Ainsworth BE. Quantifying energy expenditure and physical 
activity in the context of dose response. Med. Sci. Sports Exerc. 2001; 33: S370–
S378; discussion S419–S420. 
 
33.  Westerterp KR. Assessment of physical activity: a critical appraisal. Eur. J. Appl. 
Physiol. 2009; 105: 823–828. 
 
34.  Shephard RJ. Limits to the measurement of habitual physical activity by 
questionnaires. Br. J. Sports Med. 2003; 37: 197–206; discussion 206. 
 
35.  Williams K, Frei A, Vetsch A, Dobbels F, Puhan MA, Rüdell K. Patient-reported 
physical activity questionnaires: a systematic review of content and format. 
Health Qual. Life Outcomes 2012; 10: 28. 
 
36.  Vilaró J, Gimeno E, Sánchez Férez N, Hernando C, Díaz I, Ferrerc M, Roca J, 
Alonso J. Daily living activity in chronic obstructive pulmonary disease: 
validation of the Spanish version and comparative analysis of 2 questionnaires. 
Med. Clínica 2007; 129: 326–332. 
 
37.  Steele BG, Holt L, Belza B, Ferris S, Lakshminaryan S, Buchner DM. 
Quantitating physical activity in COPD using a triaxial accelerometer. Chest 
2000; 117: 1359–1367. 
 
38.  Patel SA, Benzo RP, Slivka WA, Sciurba FC. Activity monitoring and energy 
expenditure in COPD patients: a validation study. COPD 2007; 4: 107–112. 
 
39.  Bossenbroek L, de Greef MH, Wempe JB, Krijnen WP, Hacken NH Ten. Daily 
physical activity in patients with chronic obstructive pulmonary disease: a 
systematic review. COPD 2011; 8: 306–319. 
 
40.  Vorrink SN, Kort HS, Troosters T, Lammers J-W. Level of daily physical activity 
in individuals with COPD compared with healthy controls. Respir Res 2011; 12: 
33. 
 
41.  Remoortel HV, Hornikx M, Demeyer H, Langer D, Burtin C, Decramer M, 
Gosselink R, Janssens W, Troosters T. Daily physical activity in subjects with 
newly diagnosed COPD. Thorax 2013; 68: 962–963. 
 
42.  Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with 
COPD. Eur Respir J Off J Eur Soc Clin Respir Physiol 2009; 33: 262–272. 
 
43.  Hernandes NA, Teixeira D de C, Probst VS, Brunetto AF, Ramos EMC, Pitta F. 
Profile of the level of physical activity in the daily lives of patients with COPD in 
Brazil. J Bras Pneumol Publicaça̋o Of Soc Bras Pneumol E Tisilogia 2009; 35: 
949–956. 
 
44.  Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical 
activity and hospitalization for exacerbation of COPD. Chest 2006; 129: 536–544. 
 
   
110 
 
45.  Walker PP, Burnett A, Flavahan PW, Calverley PMA. Lower limb activity and its 
determinants in COPD. Thorax 2008; 63: 683–689. 
 
46.  Park SK, Richardson CR, Holleman RG, Larson JL. Physical activity in people 
with COPD, using the National Health and Nutrition Evaluation Survey dataset 
(2003-2006). Heart Lung J Crit Care 2013; 42: 235–240. 
 
47.  Eliason G, Zakrisson A-B, Piehl-Aulin K, Hurtig-Wennlöf A. Physical Activity 
Patterns in Patients in Different Stages of Chronic Obstructive Pulmonary 
Disease. COPD 2011; : 110906095333001. 
 
48.  Miller CK, Headings A, Peyrot M, Nagaraja H. Goal difficulty and goal 
commitment affect adoption of a lower glycemic index diet in adults with type 2 
diabetes. Patient Educ Couns 2012; 86: 84–90. 
 
49.  Benzo RP, Chang C-CH, Farrell MH, Kaplan R, Ries A, Martinez FJ, Wise R, 
Make B, Sciurba F, NETT Research Group. Physical activity, health status and 
risk of hospitalization in patients with severe chronic obstructive pulmonary 
disease. Respiration 2010; 80: 10–18. 
 
50.  Chen Y-J, Narsavage GL. Factors related to chronic obstructive pulmonary 
disease readmission in Taiwan. West J Nurs Res 2006; 28: 105–124. 
 
51.  Garcia-Aymerich J, Farrero E, Félez MA, Izquierdo J, Marrades RM, Antó JM, 
Estudi del Factors de Risc d’Agudització de la MPOC investigators. Risk factors 
of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 
2003; 58: 100–105. 
 
52.  Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical 
activity reduces hospital admission and mortality in chronic obstructive 
pulmonary disease: a population based cohort study. Thorax 2006; 61: 772–778. 
 
53.  Garcia-Rio F, Rojo B, Casitas R, Lores V, Madero R, Romero D, Galera R, 
Villasante C. Prognostic value of the objective measurement of daily physical 
activity in patients with COPD. Chest 2012; 142: 338–346. 
 
54.  Moy ML, Teylan M, Weston NA, Gagnon DR, Garshick E. Daily step count 
predicts acute exacerbations in a US cohort with COPD. PloS One 2013; 8: 
e60400. 
 
55.  Esteban C, Arostegui I, Aburto M, Moraza J, Quintana JM, Aizpiri S, Basualdo 
LV, Capelastegui A. Influence of changes in physical activity on frequency of 
hospitalization in chronic obstructive pulmonary disease. Respirology 2014; 19: 
330–338. 
 
56.  Esteban C, Quintana JM, Aburto M, Moraza J, Capelastegui A. A simple score for 
assessing stable chronic obstructive pulmonary disease. QJM Mon. J. Assoc. 
Physicians 2006; 99: 751–759. 
 
   
111 
 
57.  Esteban C, Quintana JM, Aburto M, Moraza J, Arostegui I, España PP, Aizpiri S, 
Capelastegui A. The health, activity, dyspnea, obstruction, age, and 
hospitalization: prognostic score for stable COPD patients. Respir Med 2011; 105: 
1662–1670. 
 
58.  Garcia-Aymerich J, Lange P, Serra I, Schnohr P, Antó JM. Time-dependent 
confounding in the study of the effects of regular physical activity in chronic 
obstructive pulmonary disease: an application of the marginal structural model. 
Ann Epidemiol 2008; 18: 775–783. 
 
59.  Cervera MP, Damiá A de D, Fábregas ML, Gutiérrez FJB, Torrego LC. 
Precipitating factors of mortality in chronic obstructive pulmonary disease 
patients with frequent exacerbations. Rev Clínica Esp 2010; 210: 323–331. 
 
60.  Waschki B, Kirsten A, Holz O, Müller K-C, Meyer T, Watz H, Magnussen H. 
Physical activity is the strongest predictor of all-cause mortality in patients with 
COPD: a prospective cohort study. Chest 2011; 140: 331–342. 
 
61.  Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical 
activity modifies smoking-related lung function decline and reduces risk of 
chronic obstructive pulmonary disease: a population-based cohort study. Am J 
Respir Crit Care Med 2007; 175: 458–463. 
 
62.  Lemmens KMM, Nieboer AP, Huijsman R. Designing patient-related 
interventions in COPD care: empirical test of a theoretical model. Patient Educ 
Couns 2008; 72: 223–231. 
 
63.  Garcia-Aymerich J, Serra I, Gómez FP, Farrero E, Balcells E, Rodríguez DA, de 
Batlle J, Gimeno E, Donaire-Gonzalez D, Orozco-Levi M, Sauleda J, Gea J, 
Rodriguez-Roisin R, Roca J, Agustí AG, Antó JM, Phenotype and Course of 
COPD Study Group. Physical activity and clinical and functional status in COPD. 
Chest 2009; 136: 62–70. 
 
64.  Jehn M, Schindler C, Meyer A, Tamm M, Schmidt-Trucksäss A, Stolz D. Daily 
walking intensity as a predictor of quality of life in patients with chronic 
obstructive pulmonary disease. Med Sci Sports Exerc 2012; 44: 1212–1218. 
 
65.  Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M, Pérez-Izquierdo J, 
Aizpiri S, Aguirre U, Capelastegui A. Impact of changes in physical activity on 
health-related quality of life among patients with COPD. Eur Respir J 2010; 36: 
292–300. 
 
66.  Chao PW, Ramsdell J, Renvall M, Vora C. Does a history of exercise in COPD 
patients affect functional status? A study using a lifetime physical activity 
questionnaire investigates a correlation between exercise and functional status as 
evidenced by six-minute walk distance. COPD 2011; 8: 429–436. 
 
67.  Waatevik M, Johannessen A, Hardie JA, Bjordal JM, Aukrust P, Bakke PS, Eagan 
TML. Different COPD disease characteristics are related to different outcomes in 
the 6-minute walk test. COPD 2012; 9: 227–234. 
   
112 
 
 
68.  Garcia-Rio F, Lores V, Mediano O, Rojo B, Hernanz A, López-Collazo E, 
Alvarez-Sala R. Daily physical activity in patients with chronic obstructive 
pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir 
Crit Care Med 2009; 180: 506–512. 
 
69.  Lores V, García-Río F, Rojo B, Alcolea S, Mediano O. Recording the daily 
physical activity of COPD patients with an accelerometer: An analysis of 
agreement and repeatability. Arch Bronconeumol 2006; 42: 627–632. 
 
70.  Coronado M, Janssens J-P, de Muralt B, Terrier P, Schutz Y, Fitting J-W. 
Walking activity measured by accelerometry during respiratory rehabilitation. J 
Cardpulm Rehabil 2003; 23: 357–364. 
 
71.  Howley ET. Type of activity: resistance, aerobic and leisure versus occupational 
physical activity. Med Sci Sports Exerc 2001; 33: S364–S369; discussion S419–
S420. 
 
72.  Strath SJ, Pfeiffer KA, Whitt-Glover MC. Accelerometer use with children, older 
adults, and adults with functional limitations. Med Sci Sports Exerc 2012; 44: 
S77–S85. 
 
73.  Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. 
Characteristics of physical activities in daily life in chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med 2005; 171: 972–977. 
 
74.  Troosters T, Sciurba F, Battaglia S, Langer D, Valluri SR, Martino L, Benzo R, 
Andre D, Weisman I, Decramer M. Physical inactivity in patients with COPD, a 
controlled multi-center pilot-study. Respir Med 2010; 104: 1005–1011. 
 
75.  Garcia-Aymerich J, Gómez FP, Benet M, Farrero E, Basagaña X, Gayete À, Paré 
C, Freixa X, Ferrer J, Ferrer A, Roca J, Gáldiz JB, Sauleda J, Monsó E, Gea J, 
Barberà JA, Agustí À, Antó JM. Identification and prospective validation of 
clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. 
Thorax 2011; 66: 430–437. 
 
76.  Berntsen S, Hageberg R, Aandstad A, Mowinckel P, Anderssen SA, Carlsen K-H, 
Andersen LB. Validity of physical activity monitors in adults participating in free-
living activities. Br J Sports Med 2010; 44: 657–664. 
 
77.  Sattelmair J, Pertman J, Ding EL, Kohl HW 3rd, Haskell W, Lee I-M. Dose 
response between physical activity and risk of coronary heart disease: a meta-
analysis. Circulation 2011; 124: 789–795. 
 
78.  Moore SC, Patel AV, Matthews CE, Berrington de Gonzalez A, Park Y, Katki 
HA, Linet MS, Weiderpass E, Visvanathan K, Helzlsouer KJ, Thun M, Gapstur 
SM, Hartge P, Lee I-M. Leisure time physical activity of moderate to vigorous 
intensity and mortality: a large pooled cohort analysis. PLoS Med 2012; 9: 
e1001335. 
 
   
113 
 
79.  Parker BA, Kalasky MJ, Proctor DN. Evidence for sex differences in 
cardiovascular aging and adaptive responses to physical activity. Eur J Appl 
Physiol 2010; 110: 235–246. 
 
80.  Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K, 
Holland AE, Lareau SC, Man WD-C, Pitta F, Sewell L, Raskin J, Bourbeau J, 
Crouch R, Franssen FME, Casaburi R, Vercoulen JH, Vogiatzis I, Gosselink R, 
Clini EM, Effing TW, Maltais F, van der Palen J, Troosters T, Janssen DJA, 
Collins E, Garcia-Aymerich J, Brooks D, Fahy BF, et al. An official American 
Thoracic Society/European Respiratory Society statement: key concepts and 
advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: 
e13–e64. 
 
81.  Mendoza L, Horta P, Espinoza J, Aguilera M, Balmaceda N, Castro A, Ruiz M, 
Díaz O, Hopkinson NS. Pedometers to enhance physical activity in COPD: a 
randomised controlled trial. Eur Respir J 2014; : erj00845–erj02014. 
 
82.  Suresh K. An overview of randomization techniques: An unbiased assessment of 
outcome in clinical research. J Hum Reprod Sci 2011; 4: 8–11. 
 
83.  Kawagoshi A, Kiyokawa N, Sugawara K, Takahashi H, Sakata S, Satake M, 
Shioya T. Effects of low-intensity exercise and home-based pulmonary 
rehabilitation with pedometer feedback on physical activity in elderly patients 
with chronic obstructive pulmonary disease. Respir Med 2015; 109: 364–371. 
 
84.  van Durme YMTA, Verhamme KMC, Stijnen T, van Rooij FJA, Van Pottelberge 
GR, Hofman A, Joos GF, Stricker BHC, Brusselle GG. Prevalence, Incidence, 
and Lifetime Risk for the Development of COPD in the Elderly. Chest 2009; 135: 
368–377. 
 
85.  Gershon AS, Warner L, Cascagnette P, Victor JC, To T. Lifetime risk of 
developing chronic obstructive pulmonary disease: a longitudinal population 
study. Lancet 2011; 378: 991–996. 
 
86.  Tenenbaum G, Eklund RC. Handbook of Sport Psychology. John Wiley & Sons; 
2007. 
 
87.  Mannini A, Sabatini AM. Machine Learning Methods for Classifying Human 
Physical Activity from On-Body Accelerometers. Sensors 2010; 10: 1154–1175. 
 
88.  Takeshima N, Rogers NL, Rogers ME, Islam MM, Koizumi D, Lee S. Functional 
fitness gain varies in older adults depending on exercise mode. Med Sci Sports 
Exerc 2007; 39: 2036–2043. 
 
89.  Brümmer V, Schneider S, Abel T, Vogt T, Strüder HK. Brain cortical activity is 
influenced by exercise mode and intensity. Med. Sci. Sports Exerc. 2011; 43: 
1863–1872. 
 
   
114 
 
90.  Jakicic JM, Marcus M, Gallagher KI, Randall C, Thomas E, Goss FL, Robertson 
RJ. Evaluation of the SenseWear Pro Armband to assess energy expenditure 
during exercise. Med Sci Sports Exerc 2004; 36: 897–904. 
 
91.  Vaes AW, Wouters EFM, Franssen FME, Uszko-Lencer NHMK, Stakenborg 
KHP, Westra M, Meijer K, Schols AMWJ, Janssen PP, Spruit MA. Task-related 
oxygen uptake during domestic activities of daily life in patients with COPD and 
healthy elderly subjects. Chest 2011; 140: 970–979. 
 
92.  Louvaris Z, Kortianou EA, Spetsioti S, Vasilopoulou M, Nasis I, Asimakos A, 
Zakynthinos S, Vogiatzis I. Intensity of daily physical activity is associated with 
central hemodynamic and leg muscle oxygen availability in COPD. J Appl 
Physiol 2013; 115: 794–802. 
 
93.  Spruit MA, Wouters EFM, Eterman R-MA, Meijer K, Wagers SS, Stakenborg 
KHP, Uszko-Lencer NHMK. Task-related oxygen uptake and symptoms during 
activities of daily life in CHF patients and healthy subjects. Eur J Appl Physiol 
2011; 111: 1679–1686. 
 
94.  Velloso M, Stella SG, Cendon S, Silva AC, Jardim JR. Metabolic and ventilatory 
parameters of four activities of daily living accomplished with arms in COPD 
patients. Chest 2003; 123: 1047–1053. 
 
95.  Shephard RJ. Absolute versus relative intensity of physical activity in a dose-
response context. Med Sci Sports Exerc 2001; 33: S400–S418; discussion S419–
S420. 
 
96.  Black SV, Cooper R, Martin KR, Brage S, Kuh D, Stafford M. Physical Activity 
and Mental Well-being in a Cohort Aged 60–64 Years. Am J Prev Med 2015; 49: 
172–180. 
 
97.  Dunton GF, Liao Y, Almanza E, Jerrett M, Spruijt-Metz D, Chou C-P, Pentz MA. 
Joint physical activity and sedentary behavior in parent-child pairs. Med Sci 
Sports Exerc 2012; 44: 1473–1480. 
 
98.  Dunton GF, Huh J, Leventhal AM, Riggs N, Hedeker D, Spruijt-Metz D, Pentz 
MA. Momentary assessment of affect, physical feeling states, and physical 
activity in children. Health Psychol Off J Div Health Psychol Am Psychol Assoc 
2014; 33: 255–263. 
 
 
   
115 
 
   
116 
 
ANNEXES 
 
Apart from the original papers included in the present thesis, the PhD candidate 
has also published other papers, two as first author on physical activity and three 
as second author on personal monitoring assessment.  
 
Other papers as first or second author 
 
Donaire-Gonzalez D, de Nazelle A, Cole-Hunter T, Curto A, Rodriguez D, Mendez 
M, Garcia-Aymerich J, Basagaña X, Ambros A, Jerrett M, Nieuwenhuijsen MJ.The 
Added Benefit of Bicycle Commuting on the Regular Amount of Physical Activity 
Performed. Am J Prev Med. 2015: (in Press). 
 
Rivas I, Donaire-Gonzalez D, Bouso L, Esnaola M, Pandolfi M, de Castro M, Viana 
M, Alvarez-Pedrerol M, Nieuwenhuijsen M, Alastuey A, Sunyer J, Querol X. Spatio-
temporally resolved black carbon concentration, schoolchildren's exposure and 
dose in Barcelona. Indoor Air. 2015: (in Press). 
 
Nieuwenhuijsen MJ, Donaire-Gonzalez D, Rivas I, de Castro M, Cirach M, Hoek G, 
Seto E, Jerrett M, Sunyer J. Variability in and agreement between modeled and 
personal continuously measured black carbon levels using novel smartphone and 
sensor technologies. Environ Sci Technol. 2015;49(5):2977-82.  
 
Nieuwenhuijsen MJ, Donaire-Gonzalez D, Foraster M, Martinez D, Cisneros A. 
Using personal sensors to assess the exposome and acute health effects. Int J 
Environ Res Public Health. 2014;11(8):7805-19.  
 
Donaire-Gonzalez D, de Nazelle A, Seto E, Mendez M, Nieuwenhuijsen MJ, Jerrett 
M. Comparison of physical activity measures using mobile phone-based CalFit and 
Actigraph. J Med Internet Res. 2013;15(6):e111.  
   
117 
 
  
 
 
 
 
 
 
 
Aquesta Tesi Doctoral ha estat defensada el dia  ____ d  __________________ de 20 
 
al Centre _______________________________________________________________ 
 
de la Universitat Ramon Llull 
 
davant el Tribunal format pels Doctors sotasignants, havent obtingut la 
qualificació: 
 
 
  
 
 
 
 
President/a 
 
 
 
_______________________________ 
 
 
Vocal 
 
 
 
_______________________________ 
 
 
Secretari/ària 
 
 
 
_______________________________ 
 
 
Doctorand/a 
 
 
________________________________ 
 
C.I
.F.
 G
: 5
90
69
74
0  
Un
ive
rs
ita
t R
am
on
 Lu
ll F
un
da
ció
 P
riv
ad
a. 
Rg
tr
e. 
Fu
nd
. G
en
er
al
ita
t d
e C
at
al
un
ya
 n
úm
. 4
72
 (2
8-
02
-9
0)
 
 
   C. Claravall, 1-3 
   08022 Barcelona 
   Tel. 936 022 200 
   Fax 936 022 249 
   E-mail: urlsc@sec.url.es 
   www.url.es 
 
